Enspryng Reduces Relapse Risk in Rare Autoimmune Disease MOGAD by 68%
Genentech presented results from the Phase III METEOROID study, in which satralizumab (Enspryng) significantly reduced relapse frequency in patients with MOGAD—a rare disease affecting the optic nerves, spinal cord, and brain. This is the first drug to show efficacy in this disease.
First Strike Against MOGAD: How Enspryng Changes the Game for Patients with a Rare Autoimmune Disease
Introduction
"MOGAD is a rare autoimmune disease that can attack the optic nerves, brain, and spinal cord, causing severe and unpredictable relapses that lead to accumulating neurological damage, vision loss, and disability. Currently, there are no approved treatment options for this debilitating disease."
These words belong to Michael Levy, MD, PhD, a professor at Harvard Medical School and Massachusetts General Hospital. They were spoken on April 21, 2026, at the annual meeting of the American Academy of Neurology (AAN) in Chicago—immediately after Genentech (a member of the Roche Group) presented the results of the METEOROID study.
These results proved historic: Enspryng (satralizumab) reduced the risk of new relapses in MOGAD by 68% compared to placebo, becoming the first drug to demonstrate clinically meaningful benefit in this disease in a randomized controlled trial.
MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) is a disease that was only officially recognized in recent years. Until recently, it was confused with multiple sclerosis or NMOSD, and patients received only empirical treatment with immunosuppressants of unproven efficacy. Today, that era is coming to an end.
Event Details and Timeline
What is MOGAD?
MOGAD is a rare autoimmune disease of the central nervous system caused by antibodies to the MOG protein (myelin oligodendrocyte glycoprotein). The disease primarily affects the optic nerves but can also involve the spinal cord and brain.
Key epidemiological data:
- Prevalence: according to European data, 0.51–3.42 cases per 100,000 people
- Incidence in the US: 3.4–4.8 per million people per year
- Peak incidence: childhood (under 18) and young adults (20–30 years)
- Course: 50–60% of patients have a relapsing course, with higher relapse risk in adults than in children
A hallmark of MOGAD is the accumulation of neurological damage with each new attack. Symptoms do not always fully resolve, leading to cumulative disability: vision loss, impaired mobility, cognitive dysfunction.
The METEOROID Study: Design and Participants
The METEOROID study (Phase 3) was the first-ever randomized placebo-controlled trial in MOGAD. It enrolled 132 patients aged 12 years and older with relapsing MOGAD. Participants had to have at least one relapse in the past 12 months or two attacks in the past 24 months.
Study design:
- Patients randomized 1:1 to Enspryng (n=68) or placebo (n=64)
- Enspryng administered subcutaneously at doses of 60, 120, or 180 mg depending on weight
- Dosing schedule: weeks 0, 2, and 4, then every 4 weeks
- Patients could continue background immunosuppressive therapy
- The double-blind period was event-driven—ended after 28 confirmed relapses
- Key definition of "true relapse": symptomatic attack (optic neuritis, transverse myelitis, or cerebral attack) + confirmation by new or enlarging lesion on MRI
Results: 68% Reduction in Relapse Risk
Primary endpoint (time to first relapse):
Enspryng demonstrated a statistically significant 68% reduction in the risk of a new relapse compared to placebo (p=0.0025).
| Measure | Enspryng | Placebo |
|---------|----------|---------|
| Relapse-free at 48 weeks | 87% | 67% |
| Relapse-free at 2 years | 84.3% | — |
The effect began early—as early as weeks 8–10 of treatment—and the survival curves continued to diverge throughout the study. The effect was consistent across all subgroups (age, sex, race, background immunosuppression).
Secondary endpoints:
| Measure | Effect | p-value |
|---------|--------|---------|
| Annualized relapse rate (ARR) | 66% reduction | p=0.0030 |
| Active MRI lesions | 79% reduction | p=0.0026 |
| Patients requiring rescue therapy | 73% reduction | p=0.0024 |
| Hospitalizations | 17% reduction | p=0.7528 (not significant) |
"The only thing satralizumab did not do better than placebo was reduce hospitalizations," noted Dr. Levy, adding that this point requires further analysis.
Safety:
The safety profile of Enspryng was consistent with data accumulated over more than a decade of its use in NMOSD (another autoimmune disease).
Adverse events occurring in ≥5%:
| Adverse Event | Enspryng | Placebo |
|---------------|----------|---------|
| Injection site reactions | 16% | — |
| Influenza | 9% | — |
| Arthralgia (joint pain) | 9% | — |
| Back pain | 9% | — |
| Sinusitis | 7% | — |
| Diarrhea | 6% | — |
- Treatment interruptions due to AEs: 6% (Enspryng) vs 5% (placebo)
- Serious AEs related to treatment: none
- One death (malignant melanoma)—not related to treatment
"The safety profile almost exactly matches what we saw in NMOSD studies, in terms of type and frequency of adverse events," noted Friedemann Paul from Charité University Berlin.
Impact and Significance
For Patients: End of the "Empirical" Treatment Era
Until now, patients with MOGAD and their doctors were in a paradoxical situation: the disease was recognized, but there was no approved drug for its treatment. Doctors prescribed immunosuppressants (corticosteroids, azathioprine, mycophenolate mofetil, rituximab) based only on empirical data and small observational studies.
"Patients currently receive immunosuppressants supported only by empirical evidence," explained Friedemann Paul.
Moreover, data suggested that rituximab—one of the most commonly used drugs—is less effective in MOGAD than in NMOSD. In one prospective study, MOGAD patients relapsed more frequently (37.5% vs 24%) and earlier (2.6 vs 7 months) after the last rituximab infusion compared to AQP4+ NMOSD patients.
Now, patients have the first approved drug with proven efficacy in a randomized controlled trial. This is not just a new option—it is a paradigm shift in treatment.
For Medical Science: Validation of the IL-6 Pathway in MOGAD
Enspryng's mechanism of action—blocking the interleukin-6 (IL-6) receptor—was well studied in NMOSD, where it demonstrated high efficacy. However, it was not obvious that the same mechanism would work in MOGAD, as the pathophysiology of these diseases differs.
The success of METEOROID validates the role of IL-6 in MOGAD pathogenesis and opens the door for other IL-6-targeted therapies. Researchers note that IL-6 levels are elevated in the cerebrospinal fluid and serum of MOGAD patients during attacks, and IL-6 plays a key role in T-cell activation, autoantibody stimulation, and disruption of the blood-brain barrier.
For the Pharmaceutical Industry: Market Expansion and Competition
For Roche/Genentech, the success of METEOROID represents a significant expansion of Enspryng's market potential. The drug is already approved for NMOSD in about 90 countries, and its sales in 2025 grew by 23% to 364 million Swiss francs.
Peak sales from the MOGAD indication could reach 500 million Swiss francs. Since MOGAD is rarer than NMOSD, this figure reflects not so much the population size but the premium price for the first and only approved drug in a niche with unmet need.
For Clinical Practice: What Will Change
- Possibility of early treatment initiation after MOGAD diagnosis
- Reduced uncertainty for doctors—now there is a drug with proven efficacy, rather than a choice among several off-label options with varying and unpredictable effectiveness
- Safety monitoring—mandatory screening for hepatitis B and tuberculosis before starting treatment (as in NMOSD)
Reactions from Key Players
Genentech/Roche views the result as a breakthrough. Levi Garraway, MD, PhD, Chief Medical Officer of Roche and Head of Global Product Development, stated:
"The remarkable 68% reduction in relapses observed in the METEOROID study has the potential to redefine the standard of care and become the first and only approved treatment for this debilitating rare disease. This achievement represents a breakthrough for the MOGAD community and underscores our commitment to developing new therapies that target the fundamental biology of complex neurological conditions."
The scientific community expressed cautious optimism. Michael Levy, the lead investigator, called the results "impressive" and emphasized that this is the first drug to show clinically meaningful benefit in MOGAD in a pivotal trial.
Friedemann Paul from Charité, Berlin, characterized the results as "very impressive," noting that Enspryng could become the first approved therapy to prevent attacks in MOGAD.
Investors showed restraint: the market may have already partially priced in the success, given that Enspryng is already approved for a similar disease (NMOSD) and the mechanism was biologically plausible. However, the clean result (68% reduction, p=0.0025) and consistency of secondary endpoints strengthen confidence in regulatory approval.
Outlook and Conclusions
Regulatory Path
Roche plans to submit applications for approval to the FDA and EMA in 2026. Expected FDA decision—2027. Orphan drug status for MOGAD has already been granted by the FDA.
Given:
- Lack of approved alternatives
- High statistical significance of results
- Consistent safety profile
- Mechanism already approved for NMOSD
Regulatory agencies are expected to review the application under an accelerated process.
Long-Term Questions
- What will the price be? As a first-in-class drug for a rare disease with no alternatives, Enspryng will likely command a premium price. However, healthcare systems may challenge the cost-effectiveness ratio given the relatively small patient population.
- Should all MOGAD patients be treated? 40–50% of patients have a monophasic course (only one attack in a lifetime). The decision to start therapy should consider the disease phenotype—preventive treatment is indicated only for relapsing disease.
- What are the long-term safety data? The open-label extension (OLE) of the study, in which all patients receive Enspryng for up to 2 years, will provide additional long-term safety data.
- Will there be competitors? Enspryng's success may spur development of other IL-6-targeted drugs for MOGAD, including tocilizumab, which has already shown some promising data in NMOSD.
Main Conclusion
The METEOROID study marks a historic turning point for patients with MOGAD. For the first time in the history of research into this disease (the first MOG antibodies were discovered back in 2007), they have a drug with proven efficacy in a randomized clinical trial.
A 68% reduction in relapse risk, 87% of patients relapse-free at one year, an effect starting at week 8, and a safety profile comparable to placebo—these numbers represent not just a statistical victory. They mean that MOGAD patients will no longer live in constant fear of the next unpredictable attack that could take away their vision or ability to walk.
As Michael Levy summarized: "Enspryng is the first drug to show meaningful clinical benefit for people with MOGAD in a pivotal trial, targeting the core neurological disability experienced by this patient population."
The era of "empirical" MOGAD treatment is coming to an end. The era of evidence-based therapy begins.
— Editorial Team
